Sixth measles case identified in Washington
According to Public Health – Seattle & King County, this case is not connected to any of the five previous local measles cases, which happened in Snohomish and King County. Public Health responded to three other measles cases this year among people who traveled through King County while infectious with measles but are not Washington state residents, including the recent case in a Canadian resident.
Public Health shared that the adult in this case was likely exposed to measles during recent international travel. Their vaccination status is unknown.
Saturday, May 17, 2025 from 4:45 PM - 7:20 PM
– S Concourse international arrival (Gate S8)
– International Arrivals Facility through Customs and access to baggage claim (Carousel 21)
– Exited International Arrivals Facility through Gina Marie Hall (south end of main terminal)
Sunday, May 18, 2025 from 6:00 PM – 8:20 PM
– Emergency Department entrance and waiting area
If you were at the locations at the times listed above and are not immune to measles, Public Health says the most likely time you would become sick would be between May 24, 2025 – June 8, 2025. People who are immuno-compromised may take longer to experience symptoms.
'With more measles cases globally and in the U.S., if you are planning to travel, it's always a good idea to make sure you're up to date on all your vaccinations. But if you're traveling abroad or to an area of the U.S. with a measles outbreak, it's especially important that you're well protected from measles. Vaccination will not only protect you but will also protect others you may come in contact with if you develop measles. Make sure to get vaccinated at least two weeks before your trip. This gives your body a chance to build immunity. Talk to your doctor about your family's specific health needs and travel plans,' said Meagan Kay, Medical Epidemiologist for Public Health – Seattle & King County.
For more information about measles and measles vaccination, including where to get measles vaccinations, visit: www.kingcounty.gov/measles
PREVIOUS COVERAGE:
King County Health Official: 'Measles is having a field day'
Measles identified in King County infant
King County infant with measles visited airport, hospital; not connected to previous cases
Fourth case of measles confirmed in Washington
What parents need to know about the measles vaccine
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Analysis-Wall Street sees new obesity pills as priced near Wegovy and Zepbound
By Maggie Fick and Bhanvi Satija SEATTLE (Reuters) -U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with their weight-loss injections, analysts and investors say, in a departure from the usual practice of charging more for new medicines despite pressure to cut prices. Neither drugmaker has disclosed pricing plans for their new daily oral medications. With regulatory approvals and launches still months away, pricing plans could change. Denmark-based Novo expects approval later this year and to launch soon after, while Indianapolis-based Lilly expects to launch by August 2026. Novo's Wegovy and Lilly's Zepbound, administered as weekly injections, are the only highly effective weight-loss drugs targeting the GLP-1 hormone, and the United States is their biggest market. U.S. list prices are about $1,000 per month or more, with both companies offering a monthly supply for $499 to customers paying cash rather than using health insurance. Both companies have said they developed oral weight-loss drugs to meet patient needs and widen access to the market, mindful that some people are averse to injections. The pills, however, are not more effective than the injections. Lilly said this month its pill orforglipron cut weight by 12.4% after 72 weeks in a trial. That compares with weight loss of 15% for Novo's daily oral semaglutide. Both trail Lilly's injection at up to 21%. UBS analyst Trung Huynh said that will cap Lilly's pricing. The price is "probably going to come on par with the current drugs today or slightly lower," Huynh said. TD Cowen analyst Michael Nedelcovych said he expects Novo's pill to debut near Wegovy's price, citing the precedent of its diabetes pill Rybelsus being priced at parity with injection Ozempic, the diabetes-treatment version of Wegovy. Novo executives told analysts this month they were not in a hurry for discount pricing for the new pill. Oral GLP-1 drugs will fill a niche rather than displace injections, according to analysts. TD Cowen estimates that pills will account for a percentage share of the global obesity drug market in the mid-teens by 2030, which could reach $150 billion by then. GROWING CASH PAY U.S. doctors, patients and insurers are pressing for lower prices to make the weight-loss drugs more affordable for the 40% of Americans who are obese. Typically, drugmakers launch new drugs at higher prices, citing scientific advances. President Donald Trump and lawmakers from both parties have urged the companies to reduce U.S. prices. Novo declined to comment on pricing, pointing to August 6 comments by David Moore, its U.S. operations head, saying that the company may tap customers paying cash directly via its new NovoCare pharmacy, which was launched this year to sell Wegovy outside of insurance. A Lilly spokesperson called it premature to comment on pricing and launch plans for its pill because the company has not yet submitted data for regulatory approval. Peak annual sales forecasts for Lilly's orforglipron fell to as low as $10 billion after its trial data from earlier estimates of up to $30 billion, according to a Reuters review of analyst estimates. HSBC forecasts $15 billion in peak annual sales for Novo's pill, while Barclays expects only $1 billion. MANUFACTURING VOLUME A key question is how much supply will be available at the time of launch. Shortages of injectable GLP-1s in 2023 and 2024 opened the U.S. market to cheaper compounded versions as the manufacturers failed to anticipate the huge demand. "It's all about scale and pricing," said Kevin Gade, portfolio manager at Bahl & Gaynor, which owns Lilly shares. Gade pointed to Novo's manufacturing challenge. The pill form requires about 75 times more active ingredient than the highest-dose Wegovy injection, two analysts told Reuters. Lilly has said it already has $808.5 million in orforglipron inventory for next year's expected launch. Novo has said it will launch its pill without supply constraints after billions of dollars in investment to expand semaglutide production. Despite the high production needs, Novo is unlikely to debut its pill at a higher price than Wegovy, said Karen Andersen, healthcare strategist at Morningstar. "Particularly in the growing cash-pay market, I doubt it can risk a launch at a premium to Wegovy," Andersen added. Sign in to access your portfolio
CNN
an hour ago
- CNN
Kennedy's anti-vaccine strategy risks forcing shots off market, manufacturers warn
Dining under palm trees on a patio at Mar-a-Lago in December, President-elect Donald Trump reassured chief executives at pharmaceutical giants Eli Lilly and Pfizer that anti-vaccine activist Robert F. Kennedy Jr. wouldn't be a radical choice to head the Department of Health and Human Services. 'I think he's going to be much less radical than you would think,' Trump said later that month during a news conference at his Palm Beach, Florida, resort. Eight months have passed, and Kennedy is intensifying his attacks on the vaccine system. High on his list of targets: a federal vaccine compensation program that settles injury claims. His strategy could bankrupt or diminish the fund, some legal scholars and public health leaders say, saddling pharmaceutical companies with liability risks and costs that would compel them to stop making vaccines altogether. 'It's a radical agenda,' said Angela Rasmussen, a virologist at the Vaccine and Infectious Disease Organization at the University of Saskatchewan in Canada. 'He's using a bunch of different mechanisms and there really are no guardrails. People are going to catch on but it's not going to be enough to stop the waves of deaths, and deaths of children.' Kennedy has said changes to the U.S. vaccine system are needed because, he asserts without evidence, immunizations are linked to autism, neurotoxicity, allergies, and death. He is a leader of the 'Make America Healthy Again' movement, an informal campaign that eschews traditional medicine and espouses 'medical freedom.' Many adherents oppose vaccines and believe they are unsafe despite scientific evidence to the contrary. Kennedy has acknowledged he wants to reform the vaccine fund, known as the Vaccine Injury Compensation Program, writing July 28 on the social platform X that 'the VICP is broken, and I intend to fix it.' HHS is working with the Department of Justice to revamp the program, which shields drugmakers from most liability over injuries. HHS didn't respond to a request to speak with Kennedy, but agency officials said he isn't opposed to immunizations. 'Secretary Kennedy is not anti-vaccine — he is pro-safety, pro-transparency, and pro-accountability,' HHS spokesperson Vianca Rodriguez Feliciano said in an email. Yet behind the scenes, Kennedy has been laying the groundwork to restrict the availability of widely used immunizations, according to people familiar with internal discussions who asked not to be identified because they're not authorized to speak on the topic. The strategy began taking shape in the spring. The first step: Raise unfounded questions about the safety of vaccines. At a Cabinet meeting in April, Kennedy told Trump that HHS was undertaking a massive study that would identify the cause of rising autism diagnoses by September. Kennedy tasked David Geier, a researcher who's repeated the debunked claim that vaccines cause autism, to oversee the work, according to media reports. Kennedy then doubled down by questioning the use of aluminum, which is added to many vaccines to help boost the immune response. He linked it to allergies at a July meeting of governors, even though a recent study in the Annals of Internal Medicine found no connection. He's widely expected to ask a federal vaccine advisory committee to conduct a review. The autism research and concerns about aluminum were early salvos in the push to go after the compensation fund, according to two of the people. That fund provides money to people for injuries from vaccines and has paid out more than $5 billion since it was established in 1988, according to the Health Resources and Services Administration. Before filing a lawsuit in court, injured individuals bring their claims to the program's nonjury vaccine court, which reviews evidence. The fund provides compensation from a small excise tax on vaccines. Compensation is determined in part by a table maintained by HRSA and overseen by the HHS secretary. It lists each vaccine and associated injuries and encompasses routine vaccinations recommended by the Centers for Disease Control and Prevention that are subject to the excise tax. The injuries include anaphylaxis and encephalitis. People who experience such injuries within a certain time after getting a specific vaccine can get money. Kennedy wants to get autism or allergies added to that document, according to two people familiar with internal discussions and concerns raised publicly by some vaccine developers and former regulators. He could accomplish the goal if HHS-led research blames vaccines for autism, for example, or if a federal vaccine advisory panel recommends against aluminum in vaccines, according to some legal scholars. 'Given the rate of autism, if a lot of cases are brought, that could bankrupt the program,' said Dorit Reiss, a professor at University of California Law San Francisco. If that were to happen, pharmaceutical companies could stop producing the immunizations, which don't tend to be very profitable, rather than get entangled in drawn-out, expensive lawsuits from claimants who can't get money because the federal vaccine injury fund has run dry, some legal experts and vaccine developers said. 'The compensation fund, if it's gone, would impact decisions to proceed or not to proceed,' said David Dodd, president and CEO of GeoVax Labs, a biotechnology company developing vaccines and immunotherapies. A federal vaccine advisory panel could also recommend against aluminum in shots, forcing drugmakers to make costly reformulations or exit the market. Kennedy has placed people around him to execute the strategy. He's pushed to get vaccine skeptics in decision-making positions at the CDC, which recommends vaccines, and the Food and Drug Administration, which approves them. He also tapped leaders in the anti-vaccine movement to vet candidates for him. The outcome has been regulatory and policy decisions that have winnowed vaccine access and development. HHS this month said it was halting $500 million in grants and contracts for the development of mRNA vaccines, including an improved, more durable covid mRNA vaccine. The federal government stopped recommending covid shots for healthy pregnant women and children, bypassing input from a vaccine advisory committee that traditionally would have weighed in. And Kennedy reconstituted that committee with his own handpicked members, including vaccine skeptics, and removed the American Medical Association, American Nurses Association, and other industry groups that served as committee liaisons. The modified panel recommended against flu vaccines containing a preservative erroneously linked to autism. Kennedy's determination to keep vaccine skeptics in oversight positions played out in a deal he recently made with Trump and his staff, according to two people familiar with the situation. The arrangement came together on a Sunday night in July when Kennedy got a call from the White House. The subject was Vinay Prasad, a top vaccine regulator at the FDA. He had recently touched off a wave of industry criticism for playing a role in the agency's decision to ask biotech company Sarepta Therapeutics to halt shipments of a gene therapy over safety concerns. Social media posts and conservative commentators whipped up a furor. Laura Loomer, a far-right provocateur, said July 21 on X that Prasad should be fired and called him 'a self-proclaimed progressive liberal and Bernie Sanders fanboy,' referring to Sen. Bernie Sanders (I-Vt.). Congressional lawmakers began peppering the White House with questions. The furor reached Trump, who wanted Prasad out, according to the people. But Kennedy was concerned about losing Prasad. He felt he needed a critic of immunizations overseeing vaccines at the agency. So Kennedy struck a deal. Prasad would be asked to resign as head of the FDA's Center for Biologics Evaluation and Research, which regulates vaccine products and biologics such as gene therapies. And the center would be divided into two operations, with Kennedy empowered to select the person overseeing vaccines. Some public health leaders publicly shared details of the arrangement and raised concerns about its potential impact. Former FDA Commissioner Scott Gottlieb said in an Aug. 1 interview on CNBC that he thought it 'would be very destructive to the agency.' After leaving the agency in July, Prasad is now returning, though it is unclear if his role has changed. Recently, Kennedy was sued by Ray Flores, senior outside council for the Children's Health Defense. The Children's Health Defense, an anti-vaccine group founded by Kennedy, is funding the suit, which claims Kennedy failed to launch a task force to study vaccine safety that it says is required to report findings to Congress. But Kennedy and his allies view the lawsuit as friendly, according to one person familiar with the matter, because it is seeking an outcome that he wants. HHS on Aug. 14 announced it was reviving a federal panel, disbanded in 1998, to provide oversight of pediatric vaccines. Kennedy's work against vaccines has triggered unfriendly lawsuits too, including one brought by the American Academy of Pediatrics and other public health groups. His recent decision to halt funds for mRNA vaccine development yielded a swell of social media criticism. 'This is reckless. This is dangerous. This will cost lives. We must fight back,' Sen. Edward Markey (D-Mass.) said Aug. 5 on X. 'I've tried to be objective & non-alarmist in response to current HHS actions – but quite frankly this move is going to cost lives,' Jerome Adams, who was U.S. surgeon general during the previous Trump administration, said Aug. 5 on the same platform. Kennedy and his backers remain undeterred. In a counterpunch, his supporters are launching an unprecedented public relations campaign to promote the HHS secretary, spurring speculation that he may be mulling a 2028 presidential run. The nonprofit MAHA Action held a call in July to energize Kennedy supporters and initiated a six-figure ad campaign extolling Kennedy and Trump administration health initiatives. 'Make no mistake, this is a revolution that will change the face of public health policy,' Tony Lyons, president of MAHA Action, said in a statement. 'Americans are demanding radical transparency and gold standard science.' KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF — the independent source for health policy research, polling, and journalism.
Yahoo
an hour ago
- Yahoo
New Bedford mosquito sample tests positive for West Nile virus again. What to know.
West Nile virus has been detected in a mosquito sample in New Bedford for the second time in recent weeks. The Massachusetts Department of Public Health notified local health officials about the finding, which was in a primarily bird-biting mosquito near Oak Grove Cemetery on Parker Street, according to a community announcement. The risk level for West Nile virus in New Bedford, Fairhaven and Acushnet is moderate. Preventative measures include wearing mosquito repellent between dusk and dawn, wearing long sleeves and pants during those hours, using mosquito netting on baby carriages and playpens, and emptying standing water around homes twice weekly. The Bristol County Mosquito Project conducted targeted ground-spraying Aug. 14 in the Oak Grove Cemetery area. This spraying supplements the county's normal weekly ground-spraying, which occurs seasonally from early June through September and targets parks and other locations that host large public events. Weekly sprayings take place every Thursday during the summer between 2 a.m. and sunrise in locations around Buttonwood Park, Brooklawn Park, Fort Taber, Hazelwood Park, Riverside Park, Clasky Common Park, Ashley Park, Wing's Court, Custom House Square and other parts of downtown. Residents near targeted areas may want to close their windows in the evenings before spraying. In the event of inclement weather, spraying will be moved to early Friday morning. The annual monitoring program involves crews placing traps and collecting specimens to monitor the mosquito population throughout the summer. It also helps track whether any mosquitoes are carrying Eastern equine encephalitis or West Nile virus. West Nile virus is a mosquito-borne virus that can cause illness ranging from a mild fever to more serious disease. It is most commonly spread to people through the bite of an infected mosquito. Positive mosquito samples for West Nile are not uncommon in the summer months and have been found in cities and towns across the state in recent weeks. The New Bedford Health Department recommends several precautionary measures to help protect against mosquito bites: Be aware of peak mosquito hours: Mosquitoes are most active from dusk to dawn. Consider rescheduling outdoor activities during these times or take extra precautions with repellent and protective clothing, especially if you spend a lot of time outdoors. Clothing can help reduce mosquito bites: Wearing long sleeves, long pants and socks when outdoors can help keep mosquitoes away from your skin, even though it may be challenging in hot weather. Apply insect repellent when outdoors: Use a repellent with DEET, permethrin, picaridin, IR3535 or oil of lemon eucalyptus according to the product label instructions. DEET products should not be used on infants under 2 months of age and should be used in concentrations of 30% or less on older children. Oil of lemon eucalyptus should not be used on children under 3 years of age. Permethrin products are intended for use on items such as clothing, shoes, bed nets and camping gear and should not be applied to skin. Drain standing water: Mosquitoes lay eggs in standing water. Limit breeding sites around your home by draining or removing items that hold water. Check rain gutters and drains, empty unused flowerpots and wading pools, and change water in birdbaths frequently. Install or repair screens: Some mosquitoes can enter homes. Keep them outside by ensuring tight-fitting screens on all windows and doors. For more information and the state's risk-level map, visit This story was created by reporter Beth McDermott, bmcdermott1@ with the assistance of Artificial Intelligence (AI). Journalists were involved in every step of the information gathering, review, editing and publishing process. Learn more at This article originally appeared on Standard-Times: West Nile virus detected in mosquito sample in New Bedford Solve the daily Crossword
